Results 251 to 260 of about 85,863 (303)

Individual patient data meta-analysis of placebo-controlled trials of selective serotonin reuptake inhibitors submitted for regulatory approval in adult obsessive-compulsive disorder. [PDF]

Br J Psychiatry
Cohen SE, Storosum BW, Zantvoord JB, Mattila TK, de Boer A, Denys D.   +5 more
europepmc   +1 more source

Selective Serotonin Reuptake Inhibitors and Solitary Rectal Ulcer Syndrome: A Bloody Relationship. [PDF]

Eur J Case Rep Intern Med
Moussallem N, Haddad GC, Sbeih S, Karam K, Fiani E.   +4 more
europepmc   +1 more source

Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System. [PDF]

Med Princ Pract
Elli C, Novella A, Elli C, Pasina L.
europepmc   +1 more source

Selective serotonin reuptake inhibitors (SSRIs) suppress Na⁺- dependent Mg²⁺ efflux in rat ventricular myocytes. [PDF]

J Physiol Sci
Tashiro M, Konishi M, Inoue H, Yokoyama U.   +3 more
europepmc   +1 more source

The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug-Drug Interaction Insights from EudraVigilance. [PDF]

J Clin Med
Dobrea CM, Morgovan C, Frum A, Butuca A, Chis AA, Arseniu AM, Ghibu S, Vonica RC, Gligor FG, Ilie IRP, Vonica Tincu AL.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Pharmacogenomics of Selective Serotonin Reuptake Inhibitors

Pharmacogenomics, 2022
Antidepressant medications are frequently used as the first line of treatment for depression. However, their effectiveness is highly variable and influenced by genetic factors. Recently, pharmacogenetic studies, including candidate-gene, genome-wide association studies or polygenic risk scores, have attempted to uncover the genetic architecture of ...
Luis M García-Marín, Jill A Rabinowitz, Zuriel Ceja, Sarael Alcauter, Alejandra Medina-Rivera, Miguel E Rentería   +5 more
openaire   +3 more sources

Selective Serotonin Reuptake Inhibitors in Pregnancy

Current Medicinal Chemistry, 2012
The use of antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs), during pregnancy is rapidly increasing. To date, the effects of SSRI on pregnant women and fetuses are controversial and still a matter of debate. Although a number of studies have shown that these antidepressants are not teratogenic, some of them have reported an
V, Bellissima, T F F, Ververs, G H A, Visser, D, Gazzolo   +3 more
openaire   +2 more sources

Selective Serotonin-Reuptake Inhibitors: An Update

Harvard Review of Psychiatry, 1999
Selective serotonin-reuptake inhibitors (SSRIs), including fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram, represent an important advance in the pharmacotherapy of mood and other disorders. They are chemically unrelated to tricyclic, heterocyclic, and other first-generation antidepressants.
P S, Masand, S, Gupta
openaire   +2 more sources

Selective Serotonin Reuptake Inhibitor Exposure

Topics in Companion Animal Medicine, 2013
Many antidepressants inhibit serotonin or norepinephrine reuptake or both to achieve their clinical effect. The selective serotonin reuptake inhibitor class of antidepressants (SSRIs) includes citalopram, escitalopram (active enantiomer of citalopram), fluoxetine, fluvoxamine, paroxetine, and sertraline.
Kevin T, Fitzgerald, Alvin C, Bronstein
openaire   +2 more sources